Tixagevimab/Cilgavimab for Prevention of COVID-19 during the Omicron

Surge: Retrospective Analysis of National VA Electronic Data

Yinong Young-Xu, ScD, MA, MS^{1,2}* Lauren Epstein, MD MSc^{3*} Vincent C Marconi, MD^{3,4} Victoria Davey, PhD MPH⁵ Gabrielle Zwain, BA¹ Jeremy Smith, MPH¹ Caroline Korves, ScD¹ Fran Cunningham, PharmD⁶ Robert Bonomo, MD^{7,8} Adit A Ginde, MD MPH⁹

Affiliations

¹White River Junction Veterans Affairs Medical Center, White River Junction, VT
 ²Geisel School of Medicine at Dartmouth, Hanover, NH
 ³Atlanta Veterans Affairs Medical Center, Decatur, GA
 ⁴Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA
 ⁵US Department of Veteran's Affairs, Office of Research and Development, Washington DC
 ⁶US Department of Veterans Affairs, PBM, Center for Medication Safety, Hines, IL
 ⁷US Department of Veterans Affairs, VA SHIELD, Veterans Affairs Northeast Ohio Healthcare System, Cleveland, Ohio, USA
 ⁸Case Western Reserve University, Cleveland, Ohio, USA
 ⁹Department of Emergency Medicine, University of Colorado School of Medicine, Aurora. CO

* Contributed equally to this manuscript

Corresponding author:

Adit A. Ginde, MD, MPH University of Colorado School of Medicine 12401 E. 17th Avenue, B-215 Aurora, CO 80045 Phone: (720) 848-6777 Fax: (720) 848-7374 E-Mail: adit.ginde@cuanschutz.edu

Word Count: 3,359

ABSTRACT

Background: Little is known regarding the effectiveness of tixagevimab/cilgavimab in preventingSARS-CoV-2 infection in this population, particularly after the emergence of the Omicron variant.Objective: To determine the effectiveness of tixagevimab/cilgavimab for prevention of SARS-CoV-2 infection and severe disease among immunocompromised patients.

Design: Retrospective cohort study with propensity matching and difference-in-difference analyses.

Setting: U.S. Department of Veterans Affairs (VA) healthcare system.

Participants: Veterans age \geq 18 years as of January 1, 2022, receiving VA healthcare. We compared a cohort of 1,848 patients treated with at least one dose of intramuscular tixagevimab/cilgavimab to matched controls selected from 251,756 patients who were on immunocompromised or otherwise at high risk for COVID-19. Patients were followed through April 30, 2022, or until death, whichever occurred earlier.

Main Outcomes: Composite of SARS-CoV-2 infection, COVID-19-related hospitalization, and allcause mortality. We used cox proportional hazards modelling to estimate the hazard ratios (HR) and 95% CI for the association between receipt of tixagevimab/cilgavimab and outcomes.

Results: Most (69%) tixagevimab/cilgavimab recipients were \geq 65 years old, 92% were identified as immunocompromised in electronic data, and 73% had \geq 3 mRNA vaccine doses or two doses of Ad26.COV2. Compared to propensity-matched controls, tixagevimab/cilgavimab-treated patients had a lower incidence of the composite COVID-19 outcome (17/1733 [1.0%] vs 206/6354 [3.2%]; HR 0.31; 95%CI, 0.18-0.53), and individually SARS-CoV-2 infection (HR 0.34; 95%CI, 0.13-0.87), COVID-19 hospitalization (HR 0.13; 95%CI, 0.02-0.99), and all-cause mortality (HR 0.36; 95%CI, 0.18-0.73). Limitations: Confounding by indication and immortal time bias.

Conclusions: Using national real-world data from predominantly vaccinated, immunocompromised Veterans, administration of tixagevimab/cilgavimab was associated with lower rates of SARS-CoV-2 infection, COVID-19 hospitalization, and all-cause mortality during the Omicron surge.

Keywords: COVID-19; SARS-CoV-2; monoclonal antibodies; prevention; real-world data; epropensity score matching; difference-in-difference

INTRODUCTION

Immunocompromised patients are at high risk for morbidity and mortality related to COVID-19.¹ While vaccines have helped to prevent the spread of SARS-CoV-2 and decrease the risk of severe disease in the general population, immunocompromised patients remain at higher risk for breakthrough infections and persistent viral replication.^{2,3,4,5}

The PROVENT study, a Phase 3, multicenter, randomized, placebo-controlled trial, demonstrated a single dose of intramuscular tixagevimab/cilgavimab (Evusheld, AstraZeneca) significantly reduced the incidence of symptomatic SARS-CoV-2 infection by 76.7% after 90 days in a broad population of adults with an increased risk of inadequate response to vaccination and/or increased risk of exposure to SARS-CoV-2.⁶ Based on these findings, on December 8, 2021, the US Food and Drug Administration (FDA) granted an emergency use authorization (EUA) of tixagevimab/cilgavimab as pre-exposure prophylaxis for moderate to severe immune compromised individuals or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction.⁷ The PROVENT trial also included those with chronic health conditions that could put individuals at elevated risk for complications owing to COVID-19.

Importantly, questions remain regarding effectiveness of tixagevimab/cilgavimab for the prevention of COVID-19. Only a small proportion (11%) of participants in the PROVENT trial were immunocompromised (i.e., receipt of immunosuppressive therapy, have immunosuppressive disease or cancer), and treatment effectiveness in this crucial subgroup could not be estimated in the trial. Furthermore, all participants in the PROVENT trial were unvaccinated at the time of trial entry; therefore, indications for tixagevimab/cilgavimab among vaccinated persons is unknown. Finally, follow-up of participants in the PROVENT trial ended in September 2021; therefore, an analysis regarding real-world effectiveness is needed for tixagevimab/cilgavimab among vaccinated immunocompromised patients after the emergence of the Omicron variant (December 2021 in the US).⁸

Our objective was to assess the effectiveness of tixagevimab/cilgavimab for prevention of COVID-19 during the Omicron surge using electronic data from the U.S. Department of Veterans Affairs (VA), the largest integrated health care system in the US., the largest integrated healthcare system in the US. Using propensity score matching and Difference-in-Difference (DiD) approaches, we estimated the real-world effectiveness of tixagevimab/cilgavimab among immunocompromised Veterans for the prevention of SARS-CoV-2 infection, COVID-19 related hospitalization, and all-cause mortality.

METHODS

Study Setting and Data Sources

The VA provides care to nearly 9 million Veterans at 171 medical centers and 1112 outpatient clinics across the US. The first dose of tixagevimab/cilgavimab was given at VA on January 13, 2022. We analyzed electronic health records (EHR) using the VA Corporate Data Warehouse (CDW), which contains patient-level information on all patient encounters in VA medical facilities, including treatments, prescriptions, vaccinations, laboratory results, healthcare utilization, and vital status.^{9,10} We identified tixagevimab/cilgavimab use through the VA Pharmacy Benefits Management (PBM) EUA prescription dashboard, which captures and links records of recipients, date, and dosage of tixagevimab/cilgavimab administered in medical facilities across VA.¹¹

This study was approved by the institutional review board of the VA Medical Center in White River Junction, Vermont, and was granted a waiver of informed consent because the study was deemed minimal risk and consent impractical to acquire. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

Study population and outcomes

We included Veterans who were ≥ 18 years (as of January 1, 2022) and received VA healthcare through April 30, 2022 or until death, whichever occurred earlier, and who fulfilled study period and

other inclusion criteria. Tixagevimab/cilgavimab (150 mg/150 mg) was first administered in the VA on January 13, 2022. On February 24, 2022, in response to concerns regarding effectiveness of the tixagevimab/cilgavimab against the Omicron variant, the FDA revised the EUA to increase the initial dose tixagevimab/cilgavimab to 300 mg/300 mg; patients who received the previously authorized (lower) dose were advised to receive an additional dose.¹² In our current analysis, we included any patient who received at least one dose of tixagevimab/cilgavimab during the observation period in the treatment arm. Controls were immunocompromised or other high-risk patients who did not receive tixagevimab/cilgavimab. To address immortal time bias control patients were assigned pseudo-administration dates to match the real treatment dates of the tixagevimab/cilgavimab patient cohort. These dates, real and imitated, served as the index date of follow-up. The study period was then divided into phases. We looked back over a maximum of two years before the date of treatment to assess baseline characteristics, with a follow-up period from date of receiving tixagevimab/cilgavimab through April 30, 2022, or until death, whichever occurred earlier.

Characteristics measured during the baseline period included demographics, significant comorbidities, and healthcare utilization. We used VA-assigned priority group for healthcare to serve as a surrogate measure for socioeconomic status.¹³ Information regarding comorbidities was abstracted from diagnosis codes recorded in VA electronic data for healthcare encounters during any VA visit in the two years before the index date; significant comorbidities were defined according to an adaptation of Deyo-Charlson comorbidity index (DCCI).¹⁴ We defined immunocompromised status based on 1) whether the patient received an immunosuppressive medication during the 30 days before the index date (Appendix I) or 2) the presence of at least one qualifying immunocompromising condition, based on ICD-10 code listed in Appendix II, during the two years before index date.¹⁵ We defined severely immunocompromised as those who had a solid organ transplant or received anti-rejection medication for transplant or chemotherapy for cancer treatment in the prior month.

The primary outcome was the composite of 1) SARS-CoV-2 infections confirmed by the presence of SARS-CoV-2 virus detected by reverse-transcriptase-polymerase-chain-reaction (RT-PCR) or antigen testing; 2) COVID-19 hospitalization, defined as having both an admission and discharge diagnosis for COVID-19 from a hospital or within 30 days of positive SARS-CoV-2 RT-PCR result or antigen test; 3) all-cause mortality, defined as having a date of death (DoD) during the follow-up. Clinical visits with urinary tract infection (UTI) as the primary discharge diagnosis (UTI, ICD-9: 599) were added as a fourth outcome in falsification test as for a negative control.¹⁶

Statistical Analysis

Propensity Score Matching

We used propensity score models to account for observable baseline differences between patients who received tixagevimab/cilgavimab and controls. All covariates in the propensity score (Appendix III) were measured before the initiation of tixagevimab/cilgavimab to avoid adjustment for potential mediators. Indicator variables were generated to capture missing or unknown values for any of the matching criteria to retain patients in the study. Propensity score matching was performed using greedy nearest neighbor matching with caliper of 0.2 and ratio of 1:4 with replacement.¹⁷ In order to assess the robustness of the propensity match, we calculated the standardized mean difference (SMD); a successful match was estimated when at least 90% of the covariates included in the propensity score model had Standardized Mean Difference (SMD) of ≤ 10 .¹⁸

To address immortal time bias,¹⁹ we generated a pseudo-tixagevimab/cilgavimab administration date for each control that follows the same distribution as those actual administration dates for recipients of tixagevimab/cilgavimab.²⁰ In the final model, we matched patients who received tixagevimab/cilgavimab and eligible controls based on the date (or pseudo-date) and the facility where tixagevimab/cilgavimab was administered. We excluded any patients who were diagnosed with SARS-CoV-2 infection via a positive RT-PCR result or antigen testing within 3 months of the date or pseudodate of tixagevimab/cilgavimab administration to optimize focus on new infections. We used Cox proportional hazards regression to compare patients who received tixagevimab/cilgavimab and their matched controls.

Difference-in-Difference Analysis

In addition to the propensity score model, we used a difference-in-difference (DiD) analysis to assess outcomes. The DiD analysis is a quasi-experimental method used to estimate the causal effect of an intervention.²¹ We calculated a person-time denominator for patients who received tixagevimab/cilgavimab and controls by tallying the number of days those patients were enrolled for an extended study period (September 1, 2021 through April 30, 2022). We calculated a numerator as total number of outcomes (including multiple outcomes for a single patient) per period. Outcome rates were then calculated for treated and controls during the baseline (last 4 months of 2021) and observation period. To simplify, we calculated events by calendar month. This was only employed to show the background rates of events during this extended period for the unmatched study population.

After propensity-score matching, we adjusted for residual confounding using the prior event rate ratio (PERR) approach.²² This method, like the difference-in-differences method used in econometrics, accounts for two distinct time periods, time before the intervention (e.g., tixagevimab/cilgavimab administration date and pseudo- tixagevimab/cilgavimab administration date) and time after the intervention. For each cohort, the rates of each outcome were calculated and compared before and after the intervention within the extended study period. To assess the impact of the intervention, the relative rate of the post-treatment period was divided by the relative rate of the pre-treatment period.

To apply the PERR method, we first computed the incidence rate ratio (RR) for each study outcome in the observation period (RR_o) and then again in the baseline period (RR_b). The RR is the rate of the outcome among tixagevimab/cilgavimab recipients divided by the rate of the outcome in the

control arm. Next, we computed the PERR per the following formula PERR=(RRo / RR_b), and, finally, the relative effectiveness of tixagevimab/cilgavimab to SPM (rE) is defined as (1-PERR) x 100%.

Analyses were performed with Stata 17 software (StataCorp), and SAS software, version 8.2 (SAS Institute).

RESULTS

Study Population

We identified 1,848 recipients of tixagevimab/cilgavimab and 251,756 control patients who were immunocompromised or otherwise at high risk for COVID-19 (Figure 1). After propensity-score matching 1,733 remained in the treatment group and 6,354 in the control group, which were well balanced across baseline characteristics (Table 1). Among the treated, 1,579 (91%) were male, 277 (16%) were Black, 76 (4%) were Hispanic, and 1250 (72%) were non-Hispanic White. Most (1,187 [69%]) of the tixagevimab/cilgavimab recipients were \geq 65 years old and 1,238 (71%) lived in urban areas.²³ We identified 1,595 (92%) tixagevimab/cilgavimab recipients as immunocompromised in the electronic data (by immunosuppressants use and diagnosis codes in Appendix Tables I, II). The propensity-matched control group had the same proportion of immunocompromised patients (5,863 [92%]). Additional common comorbidities in treated patients included 1,029 (59%) hypertension, 612 (35%) dyslipidemia, 597 (34%) cancer, and the majority were overweight (BMI $[kg/m^2] \ge 25.0$ and <30. 674 [39%]) or obese (BMI 30.0 or higher, 632 [36%]). Most tixagevimab/cilgavimab recipients had received 2 doses of mRNA vaccines or 1 dose of Ad26.COV2 (Janssen) (22%) or \geq 3 vaccine doses or 2 doses of Ad26.COV2 (73%). Only 88 (5%) tixagevimab/cilgavimab recipients did not have any record of COVID-19 vaccination, compared to 67,753 (27%) among unmatched control patients.

To provide an overall picture of SARS-CoV-2 infection data for the study population during the extended study period, we displayed SARS-CoV-2 infection by calendar month from September 2021 to

April 2022 with January 2022 as division when tixagevimab/cilgavimab first became available in the VA (**Figure 2**). Immunocompromised Veterans who received tixagevimab/cilgavimab (1,848) were shown next to the control group of 251,756 who did not receive tixagevimab/cilgavimab in categories of identified events: SARS-CoV-2 infection verified by positive PCR test, COVID-19-related hospitalization, all-cause mortality. During the last 4 months of 2021, before tixagevimab/cilgavimab became available at VA, the treatment group had an average incidence of SARS-CoV-2 infection or COVID-19-related hospitalization at 0.6% per month, while the control group had an average incidence of 0.8% per month. With the Omicron surge in January 2022, the first 4-month average in 2022 increased to 0.9% and 1.4% for the treatment and control groups, respectively. Although both groups experienced a surge, the treatment group was proportionally smaller than that of the control group (50% vs. 75% increase).

Propensity Score Analysis

Estimated from propensity-score matched survival analyses, tixagevimab/cilgavimab recipients had a lower incidence of the composite of COVID-19 outcomes versus control patients overall (17/1733 [1.0%] vs 206/6354 [3.2%]; HR 0.31; 95%CI, 0.18-0.53). Results were similar within the study populations of EHR-confirmed immunocompromised (HR 0.32; 95%CI, 0.18-0.62), severely immunocompromised (HR 0.44; 95%CI, 0.21-0.93), and for Veterans aged 65 or older (HR 0.33; 95%CI, 0.18-0.61). The association in the overall cohort was similar across each of the individual COVID-19 outcomes, including test-confirmed SARS-CoV-2 infection (HR 0.34; 95%CI, 0.13-0.87), COVID-19 hospitalization (HR 0.13; 95%CI, 0.02-0.99), and all-cause mortality (HR 0.36; 95%CI, 0.18-0.73). (Table 2, Figure 3)

Lastly, we were able to examine the impact of tixagevimab/cilgavimab with and without concomitant vaccination. Those fully vaccinated with at least 3 doses of any vaccine or 2 doses of Ad26.COV2, but without receiving tixagevimab/cilgavimab, had an incidence rate of 2.8% of COVID-

19 infection or related hospitalization vs a rate of 3.7% among those neither vaccinated nor received tixagevimab/cilgavimab. Those not fully vaccinated but treated with tixagevimab/cilgavimab had an incidence rate of 1.35%. Most dramatically, those who were both fully vaccinated and received tixagevimab/cilgavimab had a rate of 0.85%, like the rate of a fully vaccinated and boosted non-immunocompromised adult.²⁴

Sensitivity (DiD) Analysis

The interaction term between intervention (tixagevimab/cilgavimab vs control) and period (baseline and observation) was used to estimate the PERR-adjusted effectiveness using a Poisson regression model. The matched, PERR-adjusted effectiveness, as measure by incidence rate ratio was 0.32 (95% CI, 0.24-0.44%) against SARS-CoV-2 infection verified by a positive test, 0.10 (95% CI, 0.05-0.22) against COVID-19-related hospitalization, almost identical to the point estimates from propensity-scores matched survival analysis (**Table 2**). Because both actual and pseudo tixagevimab/cilgavimab use required the subjects to be alive, we were not able to perform PERR analysis on mortality, including the composite outcome.

Falsification Analysis

Healthcare encounters with UTI as the primary discharge diagnosis were unlikely to be associated with tixagevimab/cilgavimab; therefore, served as a falsification test. One hundred sixty-three UTI visits were observed during the follow-up period. Propensity scores matched analysis demonstrated a similar effectiveness of tixagevimab/cilgavimab versus control against UTI (HR 1.05; 95% CI, 0.68-1.62) (**Table 2**). This lack of association between UTI and the treatment is reassuring that the protective effects associated with the treatment of tixagevimab/cilgavimab were unlikely due to bias or other major methodological flaws.

DISCUSSION

In this retrospective cohort study using real-world data from patients across the VA healthcare system in the US, administration of tixagevimab/cilgavimab was associated with a significant reduction in the risk of SARS-CoV-2 infection, COVID-19 hospitalization, and all-cause mortality among patients who received tixagevimab/cilgavimab compared with controls. Our findings were consistent across two robust statistical approaches, including propensity score matching and DiD estimations. These findings were observed among immunocompromised, severely immunocompromised, and older patients, further supporting the EUA criteria for use of tixagevimab/cilgavimab in this population. Further, we found evidence of augmented protection against SARS-CoV-2 infections among fully vaccinated immunocompromised patients who received tixagevimab/cilgavimab, akin to that of the population of fully boosted adults who were not immunocompromised.²⁴

To our knowledge, this is the first real-world evidence of tixagevimab/cilgavimab for prevention of COVID-19 and provides important insights regarding the patient population who have received tixagevimab/cilgavimab across VA healthcare system. Of note, the EUA encourages use of tixagevimab/cilgavimab primarily among fully vaccinated immunocompromised patients; however, none of the participants in the PROVENT trial were vaccinated. In comparison, **Error! Bookmark not defined.** nearly all (95%) of our study population received at least two doses of a COVID-19 mRNA vaccine or one dose of Ad26.COV2 before receiving tixagevimab/cilgavimab, and most (75%) were fully vaccinated. In PROVENT, only 11% of trial participants were immunocompromised, compared to at least 92% in the current analysis. Furthermore, patients aged 65 years and older accounted for a small proportion (24%) of patients included in the PROVENT trial, compared to 69% of tixagevimab-cilgavimab recipients in the current study. However, only a small proportion of eligible patients received treatment, indicating that enhanced education and outreach are paramount to ensure that more

12

immunocompromised Veterans across the VA healthcare system receive this medication, specifically during COVID-19 surges.

In comparison to the PROVENT trial, the observation period of our analysis coincided with the Omicron BA.1 surge across the United States and provides important clinical data in this latest evolution of the pandemic. While tixagevimab/cilgavimab is maintained neutralization against the Delta variant of SARS-CoV-2, tixagevimab/cilgavimab was shown to have decreased neutralizing activity against the Omicron BA.1 variant, prompting the FDA's revision of EUA to increase the initial dose tixagevimab/cilgavimab. Current data indicate that tixagevimab/cilgavimab maintains neutralization against Omicron BA.2 and BA.2.12.1, but this effect may be attenuated with BA.4 and BA.5.^{25,26,27,28}

The present analysis supports the effectiveness of tixagevimab/cilgavimab in preventing SARS-CoV-2 infections caused by the Omicron variants, including predominantly BA.1 and the early BA.2 and BA.2.12.1 surge. Future longitudinal analyses will focus on newer Omicron variants. To help address this issue, the VA has launched several initiatives including VA SHIELD (Science and Health Initiative to Combat Infectious and Emerging Life-threatening Diseases), a comprehensive biorepository of specimens from a cohort of affected Veterans with accompanying clinical data. As part of the future of VA SHIELD, clinical specimens will be collected prospectively from patients, which will help identify emerging strains as well as developing resistance in real world clinical settings. Obtaining this information rapidly will help public health officials, clinicians and researchers make important, timely decisions regarding diagnostics, prophylaxis, and therapeutics.

Our study had several notable strengths. We analyzed 1,486 patient-years of observation, making our study one of the largest ever conducted to assess tixagevimab/cilgavimab effectiveness while they were being distributed to combat a concurrent surge of the pandemic. The large sample allowed us to adjust for more potential confounding variables. Previous studies have shown that EHR data are more likely to be complete in capturing medical conditions and have a lower risk of up-coding.^{29,30}

13

Nevertheless, conventional analytical strategies such as stratification, matching (with or without propensity score), and multivariate regression analysis cannot adequately adjust for unobserved confounders. ^{31,32,33} These results were confirmed using two different statistical methods, including propensity-score matched models and DiD analysis. Propensity score matching of the intervention and comparison cohorts is an effective approach to control confounding. In addition, we employed an econometric technique – Difference-in-Difference (DiD) method - to adjust for bias from measured and unmeasured confounders and estimate the effectiveness of tixagevimab/cilgavimab in preventing COVID-19-related outcomes.

Finally, immortal time bias occurs when participants of a cohort study cannot experience the same outcome during a follow up period; if immortal time is misclassified or excluded during the analysis, the outcomes may be skewed. To account for immortal time bias in our analysis, we used a propensity-score matched survival analysis with Cox proportional hazards model to ensure controls were alive and COVID-free on the same day when their matched patients received tixagevimab/cilgavimab. This approach also ensured similar lengths of follow-up between the recipients and their matched controls.

Limitations

There are some limitations to acknowledge. Firstly, VA data include only healthcare encounters occur in VA medical centers, so we could have missed some infections and hospitalizations that occurred outside VA, which could bias our results towards the null. Secondly, while the EUA criteria are intended for patients who are immunocompromised, a small proportion of patients (%) who received tixagevimab/cilgavimab were not immunocompromised based on our definition and it is possible that we misclassified these patients. Thirdly, the VA has a unique population (mostly male, older), and our results may not be generalizable to a larger population of patients that were not treated at the VA. ³⁴ Fourthly, the 10th revision of the International Statistical Classification of Diseases and Related Health

Problems (ICD-10) codes from claims data have been shown to inadequately capture comorbidity and functional status.³⁵ Because only 289 (17%) of patients in our propensity-score matched tixagevimab/cilgavimab cohort received a single dose of 150 mg/150 mg tixagevimab/cilgavimab, we did not have the sufficient sample size to compare the original dosage of 150mg/150mg to the revised dosage of 300mg/300mg to assess the optimal dosing of tixagevimab/cilgavimab in the current analysis. Finally, we could not assess optimal timing of tixagevimab/cilgavimab in relation to COVID-19 vaccine administration, nor could we identify a target population who would be optimal to receive tixagevimab/cilgavimab.

Conclusion

Using national real-world data from predominantly vaccinated, immunocompromised Veterans, we found that administration of tixagevimab/cilgavimab was associated with lower rates of SARS-CoV-2 infection, COVID-19 hospitalization, and all-cause mortality, compared with controls, during the Omicron surge. Our results suggest that tixagevimab/cilgavimab administration, in addition to vaccination, protects vulnerable patients from SARS-CoV-2 infection and severe COVID-19 in a contemporary phase of the pandemic. Ongoing real-world data will help to understand the effectiveness of tixagevimab/cilgavimab for pre-exposure prophylaxis over time and against emerging variants.

The contents of this article do not represent the views of the U.S. Department of Veterans Affairs or the U.S. Government. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Food and Drug Administration, as well as any other agency of the U.S. Government. Assumptions made within and interpretations from the analysis do not necessarily reflect the position of any U.S. Government entity.

Acknowledgements

We thank Dr. Hector Izurieta for his insight on observational study methods and guidance on real-world data.

Funding Statement

Supported by the Department of Veterans Affairs (VA) Office of Research and Development, the VA Office of Rural Health, Clinical Epidemiology Program at the White River Junction VA Medical Center, by resources and the use of facilities at the White River Junction VA Medical Center and VA Informatics and Computing Infrastructure, and data from the VA COVID-19 Shared Data Resource.

Declaration of Authors Competing Interests

VCM has received investigator-initiated research grants (to the institution) and consultation fees (both unrelated to the current work) from Eli Lilly, Bayer, Gilead Sciences and ViiV. YYX, GZ, CK, JS reported receiving grants from the US Food and Drug Administration through an interagency agreement with the Veterans Health Administration and from the US Department of Veterans Affairs Office of Rural Health. YYX, GZ, JS also reported receiving funding from Pfizer to US Department of Veterans Affairs for other research projects outside the submitted work. AAG received COVID-19 research project funding from the National Institutes of Health, Department of Defense, Centers for Disease Control and Prevention, AbbVie, and Faron Pharmaceuticals, outside the submitted work.

No other disclosures were reported.

	Befo	ore Matching		Aft	er Matching	
	Controls (N= 251,756)	Tixagevimab /Cilgavimab (N= 1,848)	SMD	Controls (N= 6,354)	Tixagevimab /Cigavimab (N= 1,733)	SMD
		Sex				
Male	222,642 (88%)	1,688 (91%)	9.7	5,796 (91%)	1,579 (91%)	-0.4
		Age at 31 Dec 2	021			
Mean (St Dev)	64.6 (14.7)	67.5 (10.9)	22.6	68.1 (11.5)	67.4 (11.0)	-5.7
		Age Categor	у			
18-49	41,873 (17%)	131 (7%)	-29.8	493 (8%)	126 (7%)	-1.9
50-64	63,835 (25%)	448 (24%)	-2.6	1,378 (22%)	420 (24%)	6.1
65-69	31,171 (12%)	291 (16%)	9.7	952 (15%)	268 (15%)	1.3
70-74	52,227 (21%)	531 (29%)	18.6	1,861 (29%)	491 (28%)	-2.1
75-79	34,498 (14%)	300 (16%)	7.1	1,125 (18%)	284 (16%)	-3.5
>79	28,152 (11%)	147 (8%)	-11	545 (9%)	144 (8%)	-1
		Race / Ethnici	ty			
Black: non-Hispanic Black	49,021 (19%)	285 (15%)	-10.7	804 (13%)	277 (16%)	9.5
Hispanic any race	15,899 (6%)	79 (4%)	-9.1	237 (4%)	76 (4%)	3.3
Other	18,802 (7%)	139 (8%)	0.2	452 (7%)	130 (8%)	1.5
White: non-Hispanic White	168,034 (67%)	1,345 (73%)	13.2	4,861 (77%)	1,250 (72%)	-10
	Nu	mber of vaccin	ations			
0 dose vaccine	67,753 (27%)	98 (5%)	-61.5	286 (5%)	88 (5%)	2.7
1 dose mRNA vaccine	0	0	0	0	0	
2 dose vaccine (includes 1 dose of Janssen)	108,134 (43%)	386 (21%)	61.5	1,377 (21%)	385 (22%)	-2.7
3rd dose of vaccine	75,869 (30%)	1,364 (74%)	97.2	4,691 (74%)	1,260 (73%)	-2.5
		BMI Categor	У			
Missing	11,478 (5%)	55 (3%)	-8.3	239 (4%)	52 (3%)	-4.2
Normal	56,600 (22%)	530 (29%)	14.2	1,703 (27%)	493 (28%)	3.7
Overweight / obese	183,678 (73%)	1,263 (68%)	-10.1	4,412 (69%)	1,188 (69%)	-1.9

Table 1. Selected* Baseline Characteristics

Table 1 (continued)

	Before Matching			After Matching		
	Controls (N= 251,756)	Cases (N= 1,848)	SMD	Controls (N= 6,354)	Cases (N= 1,733)	SMD
	Deyo-Charls	on Comorbidity	y Index (DCCI)		
Mean St Dev	1.6 (2.1)	2.7 (2.3)	52.1	2.4 (2.3)	2.6 (2.3)	9.7
	High	n Risk Comorbi	dities			
Asthma	41,011 (16%)	313 (17%)	1.7	958 (15%)	289 (17%)	4.4
Cancer	30,842 (12%)	670 (36%)	58.3	1,844 (29%)	597 (34%)	11.7
Coronary Artery Disease	35,504 (14%)	312 (17%)	7.7	1,041 (16%)	286 (17%)	0.3
Cancer Metastatic	7,327 (3%)	49 (3%)	-1.6	325 (5%)	49 (3%)	-11.7
Congestive Heart Failure	17,451 (7%)	190 (10%)	12	485 (8%)	173 (10%)	8.3
Chronic Kidney Disease	26,551 (11%)	442 (24%)	36	1,125 (18%)	391 (23%)	12.1
Chronic Obstructive Pulmonary Disease	44,214 (18%)	347 (19%)	3.2	1,056 (17%)	321 (19%)	5
Cardiovascular disease	11,256 (4%)	86 (5%)	0.9	318 (5%)	74 (4%)	-3.5
Dementia	4,057 (2%)	S (S)	S	89 (1%)	S (S)	S
Diabetes Mellitus w/ complications	26,865 (11%)	293 (16%)	15.3	815 (13%)	268 (15%)	7.6
Diabetes Mellitus w/o complications	41,315 (16%)	291 (16%)	-1.8	1,021 (16%)	275 (16%)	-0.5
Hypertension	130,311 (52%)	1,111 (60%)	16.9	3,694 (58%)	1,029 (59%)	2.5
Liver disease, mild	12,834 (5%)	167 (9%)	15.4	455 (7%)	160 (9%)	7.6
Liver disease, severe	1,367 (1%)	32 (2%)	11.2	60 (1%)	27 (2%)	5.5
Renal disease	28,839 (11%)	488 (26%)	38.9	1,312 (21%)	429 (25%)	9.8
	Im	nmunocompron	nised			
Based on diagnoses	81,540 (32%)	1,336 (72%)	87.2	4,225 (66%)	1,226 (71%)	9.2
Based on diagnoses or use of immunosuppressants	211,390 (84%)	1,707 (92%)	26.2	5,863 (92%)	1,595 (92%)	-0.9
minunosuppressants						

* See Appendix II for complete definitions of variables and Appendix III for distribution of all the baseline characteristics

Table 2. Relative Effectiveness of Tixagevimab/Cilgavimab versus Untreated Controls using Propensity-Score Matched Analysis and Difference-in-Difference


	Matched Controls N=6,354	Tixagevimab/cilgavimab recipients N=1,733	Propensity Score Survival Analysis	Difference in Difference^ Analysis
	Number of Events (%)	Number of Events (%)	Hazard Ratio (95% CI)	Incidence Rate Ratio (95% CI)
Composite outcome	(COVID-19 in	fection, COVID-19 hospitaliz	zation, and all-cause mortality)	
Overall Cohort	206 (3.2%)	17 (1.0%)	0.31 (0.18-0.53)	
Immunocompromised	147 (3.5%)	12 (1.0%)	0.32 (0.18-0.62)	
Severely Immunocompromised	87 (3.7%)	11 (1.4%)	0.44 (0.21-0.93)	
Not Immunocompromised* but at High Risk	59 (2.8%)	(<1%) ^{&}	0.27 (0.13-0.56)	
	Indivi	dual Outcome (Overall Coho	rt)	
COVID-19 Infection	69 (1%)	$(<0.5\%)^{\&}$	0.34 (0.13-0.87)	0.32 (0.24-0.44)
COVID-19 related hospitalization	38 (0.5%)	(<0.5%) ^{&}	0.13 (0.02-0.99)	0.10 (0.05-0.22)
All-cause Mortality	99 (2%)	(<0.5%) ^{&}	0.36 (0.18-0.73)	
Falsification: Urinary Tract Infection	127 (2%)	36 (2%)	1.05 (0.68-1.62)	


^ DiD analysis was not performed on outcomes involving mortality data because matched cohorts were all alive at index dates.


* Electronic data regarding immunocompromised conditions or immunosuppressant use were found.

& Numbers not shown to protect patient information.

Figure 1. Selection of Patients










Figure 3. Cumulative Risk of Composite COVID-19 Outcomes for Tixagevimab-Cilgavimab Recipients Compared to Untreated Controls

Composite COVID-19 outcomes were SARS-CoV-2 infection, COVID-19 hospitalization, or all-cause mortality

SUPPLEMENTARY APPENDIX

Abemaciclib	Chlorambucil	Glasdegib	Nilutamide	Tacrolimus
Abiraterone	Cladribine	Goserelin Acetate	Niraparib	Talazoparib
Acalabrutinib	Cobimetinib	Guselkumab	Obinutuzumab	Tamoxifen
Afatinib	Cortisone	Hydroxyurea	Ofatumumab	Tazemetostat
Alectinib	Crizotinib	Ibrutinib	Olaparib	Temozolomide
Alpelisib	Cyclophosphamide	Idelalisib	Omalizumab	Tepotinib
Anastrozole	Cyclosporine	Imatinib	Osimertinib	Thioguanine
Apalutamide	Dabrafenib	Infliximab	Palbociclib	Tivozanib
Apremilast	Darolutamide	Infliximab-Abda	Panobinostat	Topotecan
Asciminib	Dasatinib	Ivosidenib	Pazopanib	Toremifene
Atezolizumab	Degarelix	Ixazomib	Pemigatinib	Trametinib
Avapritinib	Dexamethasone	Ixekizumab	Ponatinib	Tretinoin
Axitinib	Duvelisib	Lapatinib	Pralsetinib	Triptorelin
Azacitidine	Enasidenib	Larotrectinib	Prednisolone	Tucatinib
Azathioprine	Encorafenib	Letrozole	Prednisone	Umbralisib
Belumosudil	Entrectinib	Leuprolide	Procarbazine	Ustekinumab
Belzutifan	Enzalutamide	Lomustine	Regorafenib	Vandetanib
Bevacizumab	Erdafitinib	Lorlatinib	Relugolix	Vemurafenib
Bexarotene	Erlotinib	Lurbinectedin	Ribociclib	Venetoclax
Bicalutamide	Etanercept	Melphalan	Rilonacept	Vismodegib
Binimetinib	Etoposide	Mercaptopurine	Ripretinib	Vorinostat
Bosutinib	Everolimus	Methotrexate	Rucaparib	Zanubrutinib
Brigatinib	Exemestane	Methylprednisolone	Secukinumab	
Budesonide	Fludrocortisone	Midostaurin	Selinexor	
Busulfan	Fluorouracil	Mitomycin	Selpercatinib	
Cabozantinib	Flutamide	Mitotane	Sirolimus	
Canakinumab	Fulvestrant	Mycophenolate Mofetil	Sonidegib	
Capecitabine	Gefitinib	Mycophenolic Acid	Sorafenib	
Capmatinib	Gemcitabine	Neratinib	Sotorasib	
Ceritinib	Gilteritinib	Nilotinib	Sunitinib	

Appendix I. Immunosuppressants Used within 30 days before Index Date

Appendix II. Definitions of Patient Characteristics including Immunocompromised Conditions

Variable	Values	Definition	Timing
Age	Integer	Age as 31 Dec 2021	Table 1: Age as of 31 Dec 2021
Sex	Female/male	As defined in VHA data	Most recent available
Race/ethnicity	Non-Hispanic Black	Black: non-Hispanic black	Most recent available
	Hispanic any race	Hispanic: Hispanic any race	
	Non-Hispanic White	White: non-Hispanic white	
	Other	Other: non-Hispanic other race,	
		missing race, declined to state,	
		unknown	
Rurality	Highly Rural	VHA defined based on the	Most recent available
-	Rural	Rural-Urban Community Area	
	Urban	(RUCA) system [
		https://www.ruralhealth.va.gov/	
		rural-definition.asp]	
VHA defined priority	1, 2, 3, 4, 5, 6, 7, 8	VA defined based on factors	Most recent available
group		including military service	
		history, disability rating and	
		income level to identify	
		Veterans to determine	
		enrolment priority; 1 is the	
		highest priority	
		[https://www.va.gov/health-	
		care/eligibility/priority-groups/]	
Nursing home use	0/1	1 = Any nursing home or long-	During 2 years before Index date
		term care indicated on an	(from 01 Jan 2019 through Index
		inpatient admission or place of	date)
		disposition	
DCCI	Numeric	Using ICD-10 codes from any	During 2 years before Index date
		inpatient or outpatient record,	
		computed Deyo-Charlson	
		Comorbidity Index. Coding	
		algorithms for defining	
		comorbidities in ICD-9-CM	
		and ICD-10 administrative	
		data. Medical Care 2005;	
		43(11):1130-1139. DOI:	
		10.1097/01.mlr.0000182534.19 832.83]	
BMI	Normal	Normal: BMI less than 26	Most recent available from 01 Jan
Bivil	Overweight/obese	Overweight/obese: BMI greater	2018 through 30Apr2022
	Missing	than or equal to 26	2018 through 30Apr2022
Comorbidities	wiissing	All comorbidities listed below	During 2 years before Index date.
Comordiances		have 1 inpatient or 2 outpatient	During 2 years before much date.
		records with the corresponding	
		ICD-10 code	
Asthma	0/1	ICD-10 code J45*	
i southu		ICD-10 code J44.9	
		ICD-10 code J67.8	
Cancer	0/1	Charlson condition definitions	
	U/ 1		
Cancer		using (CD-10) codes	
Cancer metastatic	0/1	using ICD-10 codes Charlson condition definitions	

Coronary artery disease	0/1	ICD-10 code I 25*
Congestive heart failure	0/1	Charlson condition definitions
	0./1	using ICD-10 codes
Chronic kidney disease	0/1	ICD-10 code N18*
Chronic obstructive	0/1	Charlson condition definitions
pulmonary disease		using ICD-10 codes
Cardiovascular disease	0/1	Charlson condition definitions
		using ICD-10 codes
Dementia	0/1	Charlson condition definitions
		using ICD-10 codes
Diabetes mellitus with	0/1	Charlson condition definitions
complications		using ICD-10 codes
Diabetes mellitus without	0/1	Charlson condition definitions
complications		using ICD-10 codes
Dyslipidemia	0/1	ICD-10 code E78.5
HIV	0/1	Charlson condition definitions
HIV	0/1	
I I - we have a '	0/1	using ICD-10 codes
Hypertension	0/1	ICD-10 code H35.03*
		ICD-10 code I10*
		ICD-10 code I11*
		ICD-10 code I12*
		ICD-10 code I13*
		ICD-10 code I15*
		ICD-10 code I16
	0.44	ICD-10 code I67.4
Liver disease, mild	0/1	Charlson condition definitions
	0.44	using ICD-10 codes
Liver disease, severe	0/1	Charlson condition definitions
	0./1	using ICD-10 codes
Myocardial infarction	0/1	Charlson condition definitions
(history)	0./1	using ICD-10 codes
Para/hemiplegia	0/1	Charlson condition definitions
	0./1	using ICD-10 codes
Peptic ulcer disease	0/1	Charlson condition definitions
	0/1	using ICD-10 codes
Peripheral vascular	0/1	Charlson condition definitions
disease	0/1	using ICD-10 codes
Rheumatoid arthritis	0/1	Charlson condition definitions
	0/1	using ICD-10 codes
Renal disease	0/1	Charlson condition definitions
	0/1	using ICD-10 codes
Atrial fibrillation	0/1	ICD-10 code I48.0
		ICD-10 code I48.11
		ICD-10 code I48.19
		ICD-10 code I48.21
	0/1	ICD-10 code I48.91
Anaphylaxis (history)	0/1	ICD-10 code Z87.892
Arthritis	0/1	ICD-10 code M15* through
		M19*
Bleeding diathesis	0/1	ICD-10 code D69.9
Bronchiectasis	0/1	ICD-10 code J47*

Depression	0/1	ICD-10 code F33*
Down Syndrome	0/1	ICD-10 code Q90*
Embolism (history)	0/1	ICD-10 code I82*
		ICD-10 code I74*
	0/1	ICD-10 code I26*
Falls (history)	0/1	ICD-10 code W19*
Gout	0/1	ICD-10 code M1A*
Hepatitis B	0/1	ICD-10 code B19.1*
Hepatitis C	0/1	ICD-10 code B19.2*
Hyperlipidemia	0/1	ICD-10 code E78.2
		ICD-10 code E78.41
		ICD-10 code E78.49
		ICD-10 code E78.5
Hypersensitivity pneumonitis	0/1	ICD-10 code J67*
Interstitial lung disease	0/1	ICD-10 code J80*
Interstitian rung uisease	0/1	ICD-10 code J81*
		ICD-10 code J82*
		ICD-10 code J84*
Impaired mobility	0/1	ICD-10 code Z74.01
<u>F</u>		ICD-10 code Z74.09
Musculoskeletal disorder	0/1	ICD-10 code M00* through
		M99*
Mycoses	0/1	ICD-10 code B35* through
		B49*
Obesity	0/1	ICD-10 code E66*
Paranoia	0/1	ICD-10 code F22*
		ICD-10 code F60*
Parkinson's	0/1	ICD-10 code G20*
Pregnancy (history)	0/1	ICD-10 code Z33*
Drug-induced anaphylaxis	0/1	ICD-10 code Z88*
0:11.0.011.0.	0/1	ICD 10 and a D57*
Sickle cell disease	0/1	ICD-10 code D57*
Solid organ transplant recipient	0/1	ICD-10 code Z94*
Stroke / transient	0/1	ICD-10 code I63*
ischemic attach		ICD-10 code G45*
Urinary tract infection	0/1	ICD-10 code N39.0
Immunocompromised	0/1	ICD-10 code B20*
Conditions		ICD-10 code B20 ICD-10 code B59*
Conditions		ICD-10 code B57 ICD-10 code B97.3*
		ICD-10 code D/7.21*
		ICD-10 code D70*
		ICD-10 code D71*
		ICD-10 code D71*
		ICD-10 code D73*
		ICD-10 code D76*
L		

		ICD-10 code D80*	
		ICD-10 code D81*	
		ICD-10 code D82*	
		ICD-10 code D83*	
		ICD-10 code D84*	
		ICD-10 code D89*	
		ICD-10 code M05*	
		ICD-10 code M06*	
		ICD-10 code M07*	
		ICD-10 code M08*	
		ICD-10 code M30*	
		ICD-10 code M30*	
		ICD-10 code M31*	
		ICD-10 code M32 ICD-10 code M33*	
		ICD-10 code M35	
		ICD-10 code M34*	
		ICD-10 code M35.9*	
		ICD-10 code Q89.0*	
		ICD-10 code T45.1X1	
		ICD-10 code Z21*	
		ICD-10 code Z48.2*	
		ICD-10 code Z51.0*	
		ICD-10 code Z51.1*	
		ICD-10 code Z94*	
		ICD-10 code R76*	
		ICD-10 code Z79.5	
		ICD-10 code C00-C26	
		ICD-10 code C30-C34	
		ICD-10 code C37-C41	
		ICD-10 code C43-C58	
		ICD-10 code C60-C88	
		ICD-10 code C4A	
		ICD-10 code C7A	
		ICD-10 code C7B	
		ICD-10 code C90-C96	
		ICD-10 code D03	
		ICD-10 code D46	
		ICD-10 code Z85	
		[https://www.cdc.gov/vaccines/	
		covid-19/downloads/us-flu-	
		vaccine-effectiveness-network-	
		protocol-508.pdf]	
Hematological	0/1	ICD-10 codes 81.70, 81.79,	
malignancy		81.90	
		ICD-10 codes 82.90	
		ICD-10 codes 84.10, 84.40	
		85.80	
		ICD-10 code C88.0	
		ICD-10 code C90.00	
		ICD-10 codes C91.00, 91.01,	
		91.10, 91.11, 91.40	
		ICD-10 codes C92.00, 92.01,	
		92.10, 92.11, 92.30	
		96.2	
		ICD-10 code D47.2	
GvHd	0/1	ICD-10 code : D89.81	
	~· -		
L	1		

Vaccination status	None Full	None: until first vaccination date	Determined at date of treatment
	Booster	Full: from 14 days after the	
		second vaccination date	
		Booster: from 14 days after the	
		third vaccination date	
Vaccine manufacturer	None	None: no vaccination recorded	Determined at date of first
v accine manufacturer	Moderna	Moderna: CPT codes 91301,	vaccination
	Pfizer	0011A, 0012A, 0013A, 91306,	vaccination
	Janssen	0011A, 0012A, 0013A, 91300, 0064A or vaccination name	
	AstraZeneca	Pfizer: CPT codes 91300,	
	Astrazeneca	0001A, 0002A, 0003A, 0051A,	
		0052A, 0053A, 0054A or vaccination name	
		Janssen: 91303, 0031A, 0034A,	
		or vaccine name	
		AstraZeneca: 91302, 0021A,	
CAN C.		0022A, or vaccine name	Most moont CAN age to the 2
CAN Score		Score to identify patients at	Most recent CAN score during 2
		highest risk of hospitalization	years before and up to end of study
		and mortality. As indicated in	period 01Jan2018 through
		VHA data. If missing, the score	30Apr2022
		is assumed to be zero. [
		https://www.va.gov/HEALTHC	
		AREEXCELLENCE/about/org	
		anization/examples/care-	
		assessment-needs.asp]	
Mortality-1 year	Percentage of probability	Measurement of risk of	
	(part of CAN score)	mortality in next year	
Mortality-90 days	Percentage of probability	Measurement of risk of	
F + 1	(part of CAN score)	mortality in the next 90 days	
Event-1 year	Percentage of probability	Measurement of risk of any	
Event 00 days	(part of CAN score)	visit or event in the next year	
Event-90 days	Percentage of probability	Measurement of risk of any	
	(part of CAN score)	visit or event in the next 90	
TT '/ 1' /' 1		days	
Hospitalization-1 year	Percentage of probability	Measurement of risk of a	
	(part of CAN score)	hospitalization in the next year	
Hospitalization-90 days	Percentage of probability	Measurement of risk of a	
	(part of CAN score)	hospitalization in the next 90	
Number of an accent	Integer	days Count of VHA related	Look back period is 01 Jar 2010 (
Number of encounters	Integer	encounters (inpatient or	Look back period is 01Jan2019 to Index date
			index date
		outpatient, including	
Number of skate	Integer 0.2	telemedicine) 0 = not vaccinated	Vaccination before treatment
Number of shots	Integer 0-2		v accination before treatment
		1 = partially vaccinated with a 2-dose mRNA	
		2-dose mRNA 2 = vaccinated with 2-dose	
		2 = vaccinated with 2-dose series of mRNA or 1 Janssen	
Covid-19 before the	0/1	Positive SARS-CoV-2 lab test	Positive SARS-CoV-2 lab test at
	0/1		
Evusheld era	0/1	at VA before Index date	VA before Index date
Other control	0/1	Patients who are at high risk of	Looked for event 01Jan2019
		COVID-related morbidity and	through Index date
		mortality (Obesity, liver	
		disease, CHF, CKD, COPD,	
		adverse event from a	

		vaccination) but for whom no	
		records of either	
		immunocompromised	
		conditions or use of	
		immunosuppressants were	
		found.	
Inpatient Admission for	0/1	Having an inpatient admission	
Covid		with both an admission and	
		discharge diagnosis with	
		COVID-19 and within 30 days	
		of a positive SARS-CoV-2 lab	
		test. ICD10-CM codes: U07.1,	
		J12.82, M35.81, Z20.822,	
		M35.89	

Appendix III. All Baseline Characteristics

	Befo	re Matching		After Matching		
	Controls (N= 251,756)	Cases (N= 1,848)	SMD	Controls (N= 6,354)	Cases (N= 1,733)	SMD
		Sex				
Female	29,114 (12%)	160 (9%)	-9.7	558 (9%)	154 (9%)	0.4
Male	222,642 (88%)	1,688 (91%)	9.7	5,796 (91%)	1,579 (91%)	-0.4
Age at 31 Dec 2021 Mean St Dev	64.6 (14.7)	67.5 (10.9)	22.6	68.1 (11.5)	67.4 (11.0)	-5.7
		Age Categor				
18-49	41,873 (17%)	131 (7%)	-29.8	493 (8%)	126 (7%)	-1.9
50-64	63,835 (25%)	448 (24%)	-2.6	1,378 (22%)	420 (24%)	6.1
65-69	31,171 (12%)	291 (16%)	9.7	952 (15%)	268 (15%)	1.3
70-74	52,227 (21%)	531 (29%)	18.6	1,861 (29%)	491 (28%)	-2.1
75-79	34,498 (14%)	300 (16%)	7.1	1,125 (18%)	284 (16%)	-3.5
>79	28,152 (11%)	147 (8%)	-11	545 (9%)	144 (8%)	-1
		Race / Ethnici	ty			
Black: non-Hispanic Black	49,021 (19%)	285 (15%)	-10.7	804 (13%)	277 (16%)	9.5
Hispanic any race	15,899 (6%)	79 (4%)	-9.1	237 (4%)	76 (4%)	3.3
Other	18,802 (7%)	139 (8%)	0.2	452 (7%)	130 (8%)	1.5
White: non-Hispanic White	168,034 (67%)	1,345 (73%)	13.2	4,861 (77%)	1,250 (72%)	-10
		Rurality				
Highly rural	3,021 (1%)	18 (1%)	-2.2	69 (1%)	18 (1%)	-0.5
Rural	80,926 (32%)	507 (27%)	-10.3	1,778 (28%)	477 (28%)	-1
Urban	167,809 (67%)	1,323 (72%)	10.7	4,507 (71%)	1,238 (71%)	1.1
		mber of vaccin				
0 dose vaccine	67,753 (27%)	98 (5%)	-61.5	286 (5%)	88 (5%)	2.7
2 dose vaccine (includes 1 dose of Janssen)	184,003 (73%)	1,750 (95%)	61.5	6,068 (95%)	1,645 (95%)	-2.7
3rd dose of vaccine	75,869 (30%)	1,364 (74%)	97.2	4,691 (74%)	1,260 (73%)	-2.5
		Others				
Urinary Tract Infection	10,161 (4%)	112 (6%)	9.3	319 (5%)	106 (6%)	4.8
Nursing Home use	3,113 (1%)	31 (2%)	3.7	99 (2%)	28 (2%)	0.5
		BMI Categor	/			
BMI Mean St Dev	32.5 (357.8)	29.3 (11.8)	-1.3	30.4 (36.0)	29.3 (12.1)	-4.1
Missing	11,478 (5%)	55 (3%)	-8.3	239 (4%)	52 (3%)	-4.2
Normal: BMI less than 26	56,600 (22%)	530 (29%)	14.2	1,703 (27%)	493 (28%)	3.7
Overweight / obese: BMI greater than or equal to 26	183,678 (73%)	1,263 (68%)	-10.1	4,412 (69%)	1,188 (69%)	-1.9

Table 2 (continued)

	Befor	re Matching		Afte	r Matching	
	Controls (N= 251,756)	Cases (N= 1,848)	SMD	Controls (N= 6,354)	Cases (N= 1,733)	SMD
		Priority				
missing	S (S)	S (S)	S	S (S)	S (S)	S
1	50,829 (20%)	393 (21%)	2.7	1,169 (18%)	371 (21%)	7.5
2	19,355 (8%)	130 (7%)	-2.5	434 (7%)	124 (7%)	1.3
3	35,754 (14%)	266 (14%)	0.5	959 (15%)	250 (14%)	-1.9
4	865 (0%)	S (S)	S	20 (0%)	S (S)	S
5	52,304 (21%)	330 (18%)	-7.4	1,170 (18%)	308 (18%)	-1.7
6	24,324 (10%)	205 (11%)	4.7	720 (11%)	185 (11%)	-2.1
7	16,473 (7%)	129 (7%)	1.7	569 (9%)	121 (7%)	-7.3
8	51,805 (21%)	385 (21%)	0.6	1,311 (21%)	364 (21%)	0.9
	CHARLS	ON COMORBI	DITY IND	EX		
Mean St Dev	1.6 (2.1)	2.7 (2.3)	52.1	2.4 (2.3)	2.6 (2.3)	9.7
0	104,906 (42%)	360 (19%)	-49.6	1,581 (25%)	355 (20%)	-10.5
1	49,818 (20%)	227 (12%)	-20.6	1,044 (16%)	223 (13%)	-10.1
2	38,077 (15%)	422 (23%)	19.8	1,270 (20%)	394 (23%)	6.7
3	21,247 (8%)	260 (14%)	17.9	839 (13%)	245 (14%)	2.7
4	13,497 (5%)	205 (11%)	21	548 (9%)	186 (11%)	7.1
5 to 6	14,699 (6%)	236 (13%)	24	664 (10%)	213 (12%)	5.8
7 to 8	6,769 (3%)	105 (6%)	15	268 (4%)	91 (5%)	4.9
9+	2,743 (1%)	32 (2%)	5.4	140 (2%)	26 (2%)	-5.2
		COMORBIDITI	ES			
Asthma	41,011 (16%)	313 (17%)	1.7	958 (15%)	289 (17%)	4.4
Cancer	30,842 (12%)	670 (36%)	58.3	1,844 (29%)	597 (34%)	11.7
Coronary Artery Disease	35,504 (14%)	312 (17%)	7.7	1,041 (16%)	286 (17%)	0.3
Cancer Metastatic	7,327 (3%)	49 (3%)	-1.6	325 (5%)	49 (3%)	-11.7
Congestive Heart Failure	17,451 (7%)	190 (10%)	12	485 (8%)	173 (10%)	8.3
Chronic Kidney Disease	26,551 (11%)	442 (24%)	36	1,125 (18%)	391 (23%)	12.1
Chronic Obstructive Pulmonary Disease	44,214 (18%)	347 (19%)	3.2	1,056 (17%)	321 (19%)	5
Cardiovascular disease	11,256 (4%)	86 (5%)	0.9	318 (5%)	74 (4%)	-3.5
Dementia	4,057 (2%)	S (S)	S	89 (1%)	S (S)	S
Diabetes Mellitus w/ complications	26,865 (11%)	293 (16%)	15.3	815 (13%)	268 (15%)	7.6
Diabetes Mellitus w/o complications	41,315 (16%)	291 (16%)	-1.8	1,021 (16%)	275 (16%)	-0.5
Dyslipidemia	77,066 (31%)	656 (35%)	10.4	2,186 (34%)	612 (35%)	1.9
HIV	983 (0%)	30 (2%)	12.4	54 (1%)	22 (1%)	4.1

Table 1 (continued)

	Before Matching			After Matching		
	Controls (N= 251,756)	Cases (N= 1,848)	SMD	Controls (N= 6,354)	Cases (N= 1,733)	SMD
Hypertension	130,311 (52%)	1,111 (60%)	16.9	3,694 (58%)	1,029 (59%)	2.5
Liver disease, mild	12,834 (5%)	167 (9%)	15.4	455 (7%)	160 (9%)	7.6
Liver disease, severe	1,367 (1%)	32 (2%)	11.2	60 (1%)	27 (2%)	5.5
Myocardial infarction (history)	5,516 (2%)	68 (4%)	8.8	161 (3%)	63 (4%)	6.4
Para / hemiplegia	1,475 (1%)	26 (1%)	8.3	34 (1%)	25 (1%)	9.2
Peptic ulcer disease	1,440 (1%)	18 (1%)	4.6	49 (1%)	17 (1%)	2.3
Peripheral vascular disease	15,586 (6%)	148 (8%)	7.1	457 (7%)	140 (8%)	3.3
Rheumatoid arthritis	18,168 (7%)	200 (11%)	12.6	798 (13%)	195 (11%)	-4
Renal disease	28,839 (11%)	488 (26%)	38.9	1,312 (21%)	429 (25%)	9.8
Immunocompromised	81,540 (32%)	1,336 (72%)	87.2	4,225 (66%)	1,226 (71%)	9.2
	CARE AS	SESSMENT NE	EDS SC	ORE		
CAN Mortality 1 year Mean St Dev	0.06 (0.09)	0.09 (0.11)	34.8	0.07 (0.11)	0.09 (0.10)	13
CAN Mortality 1 year						
CAN 00 to 30	67,134 (27%)	148 (8%)	-50.9	915 (14%)	146 (8%)	-18.9
CAN 31 to 55	55,120 (22%)	262 (14%)	-20.2	1,350 (21%)	248 (14%)	-18.2
CAN 56 to 75	51,362 (20%)	459 (25%)	10.6	1,502 (24%)	439 (25%)	3.9
CAN 76 to 90	51,091 (20%)	608 (33%)	28.8	1,657 (26%)	568 (33%)	14.7
CAN 96 up	22,606 (9%)	304 (16%)	22.6	792 (12%)	269 (16%)	8.8
ENCOUNTERS						
0-9	78,582 (31%)	177 (10%)	-55.7	1,298 (20%)	164 (9%)	-31.1
10-29	109,576 (44%)	676 (37%)	-14.2	2,896 (46%)	634 (37%)	-18.4
30-59	47,472 (19%)	627 (34%)	34.7	1,578 (25%)	597 (34%)	21.2
>60	16,126 (6%)	368 (20%)	40.8	582 (9%)	338 (20%)	29.8
Other Control	40,366 (16%)	0%	-61.8	491 (8%)	0%	-40.9
Immunocompromised	211,390 (84%)	1,707 (92%)	26.2	5,863 (92%)	1,595 (92%)	-0.9
Closest VA Facility (Miles)	39.17 (130.20)	35.02 (115.05)	-3.4	33.79 (40.06)	35.98 (118.65)	2.5

References

² Embi PJ, Levy ME, Naleway AL, et al. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wklv Rep 2021:70:1553–1559.

DOI: http://dx.doi.org/10.15585/mmwr.mm7044e3

⁵ Mounzer E Agha, Maggie Blake, Charles Chilleo, Alan Wells, Ghady Haidar, Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era, Open Forum Infectious Diseases, Volume 8, Issue 7, July 2021, doi.org/10.1093/ofid/ofab353

⁶ Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, Yuan Y, Seegobin S, Ellery A, Levinson DJ, Ambery P, Arends RH, Beavon R, Dey K, Garbes P, Kelly EJ, Koh GCKW, Near KA, Padilla KW, Psachoulia K, Sharbaugh A, Streicher K, Pangalos MN, Esser MT; PROVENT Study Group. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022 Apr 20:NEJMoa2116620. doi: 10.1056/NEJMoa2116620.

⁷ https://www.fda.gov/media/154701/download, last accessed May 9, 2022

⁸ Paneth N, Joyner MJ, Casadevall A. Finding evidence for treatment decisions in a pandemic. Trends Mol Med. 2022 May 5:S1471-4914(22)00104-6. doi: 10.1016/j.molmed.2022.04.008.

⁹ https://www.hsrd.research.va.gov/for_researchers/cdw.cfm

¹⁰ https://www.hsrd.research.va.gov/for_researchers/cyber_seminars/archives/3544-notes.pdf

¹¹ https://www.pbm.va.gov/

¹² https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-revisions-evusheld-dosing

¹³ Petersen LA, Byrne MM, Daw CN, et al. Relationship between clinical conditions and use of Veterans Affairs healthcare among Medicare-enrolled veterans. Health Serv Res 2010; 45(3): 762-91.

¹⁴ Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45(6): 613-19.

¹⁵ https://covid.cdc.gov/covid-data-tracker/#variant-proportions

¹⁶ Pizer SD. Falsification testing of instrumental variables methods for comparative effectiveness research. Health Serv Res 2016; 51(2): 790-811.

¹⁷ Patrick AR, Schneeweiss S, Brookhart MA, et al. The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiology and drug safety. 2011;20(6):551-559.

¹⁸ Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. *Stat Med.* 2009;28(25):3083-3107. doi:<u>10.1002/sim.3697</u>¹⁹ Samy Suissa, Immortal Time Bias in Pharmacoepidemiology, American Journal of Epidemiology, Volume 167,

Issue 4, 15 February 2008, Pages 492–499, https://doi.org/10.1093/aje/kwm324

²⁰ Dubberke ER, Olsen MA, Stwalley D, et al. Identification of Medicare Recipients at Highest Risk for Clostridium difficile Infection in the US by Population Attributable Risk Analysis. PLoS One. 2016;11(2):e0146822. Published 2016 Feb 9. doi:10.1371/journal.pone.0146822 ²¹ Angrist JD , Pischke JS. Mastering'Metrics: The Path from Cause to Effect. Princeton, NJ: Princeton University

Press, 2014.

²² Young-Xu Y, Van Aalst R, Mahmud SM, et al. Relative Vaccine Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among Veterans Health Administration Patients. J Infect Dis. 2018 May 5;217(11):1718-1727. doi: 10.1093/infdis/jiy088.

²³ https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes/

¹ Corey L, Beyrer C, Cohen MS, Michael NL, Bedford T, Rolland M. SARS-CoV-2 Variants in Patients with Immunosuppression. N Engl J Med. 2021 Aug 5;385(6):562-566. doi: 10.1056/NEJMsb2104756.

³ Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA Covid-19 vaccine in solid organ transplant recipients. N Engl J Med 2021; 385: 661-2.

⁴ Kennedy NA, Lin S, Goodhand JR, et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut 2021; 70: 1884-93.

²⁴ Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, Mizrahi B, Alroy-Preis S, Ash N, Milo R, Huppert A. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med. 2021 Oct 7;385(15):1393-1400. doi: 10.1056/NEJMoa211425

²⁵ Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Halfmann P, Watanabe S, Maeda K, Imai M, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. N Engl J Med. 2022 Apr 14;386(15):1475-1477. doi: 10.1056/NEJMc2201933.

²⁶ Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, Bolland WH, Porrot F, Staropoli I, Lemoine F, Péré H, Veyer D, Puech J, Rodary J, Baele G, Dellicour S, Raymenants J, Gorissen S, Geenen C, Vanmechelen B, Wawina-Bokalanga T, Martí-Carreras J, Cuypers L, Sève A, Hocqueloux L, Prazuck T, Rey FA, Simon-Loriere E, Bruel T, Mouquet H, André E, Schwartz O. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022 Feb;602(7898):671-675. doi: 10.1038/s41586-021-04389-z.

²⁷ Hoffmann M, Krüger N, Schulz S, Cossmann A, Rocha C, Kempf A, Nehlmeier I, Graichen L, Moldenhauer AS, Winkler MS, Lier M, Dopfer-Jablonka A, Jäck HM, Behrens GMN, Pöhlmann S. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell. 2022 Feb 3;185(3):447-456.e11. doi: 10.1016/j.cell.2021.12.032.

²⁸ VanBlargan LA, Errico JM, Halfmann PJ, Zost SJ, Crowe JE Jr, Purcell LA, Kawaoka Y, Corti D, Fremont DH, Diamond MS. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med. 2022 Mar;28(3):490-495. doi: 10.1038/s41591-021-01678-y.

²⁹ Adler-Milstein J, Jha AK. No evidence found that hospitals are using new electronic health records to increase Medicare reimbursements. Health Aff (Millwood). 2014 Jul;33(7):1271-7.

³⁰ Devoe JE, Gold R, McIntire P, et al. Electronic health records vs Medicaid claims: completeness of diabetes preventive care data in community health centers. Ann Fam Med. 2011:9(4):351-8.
 ³¹ Psaty BM, Koepsell TD, Lin D, et al. Assessment and control for confounding by indication in observational

³¹ Psaty BM, Koepsell TD, Lin D, et al. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc **1999**; 47(6): 749-54.

³² Collard RM, Boter H, Schoevers RA, et al. Prevalence of frailty in community-dwelling older persons: A systematic review. J Am Geriatr Soc **2012**; 60(8):1487-92.

³³ Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: Evidence for a phenotype. J Gerontol A **2001**; 56(3): M146-56.

³⁴ Rogers WH, Kazis LE. Comparing the health status of VA and non-VA ambulatory patients: The Veterans' Health and Medical Outcomes Studies. J Ambul Care Manage **2004**; 27(3): 249-62.

³⁵ Mazzali C, Duca P. Use of administrative data in healthcare research. Intern Emerg Med. 2015;10(4):517-24.